FindTrial
Sign In

A study on using low dose of intravenous ketamine to manage severe cancer pain in patients with advanced stages of the cancer.

A Prospective Observational study on the efficacy and safety of low dose intravenous ketamine in refractory cancer pain in patients suffering from advanced cancer at SMS Medical College and Hospital, Jaipur - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/087182
Enrollment
85
Registered
2025-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: nil: nil

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 65 years. 2. Registered in Palliative Medicine Department. 3. Suffering from a histologically diagnosed cancer. 4. Patients having nociceptive or neuropathic pain refractory to opioids,numerical rating score greater than 7/10 5. Patient giving written informed consent for this study. 6. Patient having more than 180 mg morphine in 24 hours with inadequate pain relief.

Exclusion criteria

Exclusion criteria: 1. History of allergy or intolerance to ketamine. 2. History of uncontrolled hypertension, heart disease, liver and renal disease, glaucoma, primary and malignant brain lesions. 3. Patients on psychiatric treatment 4. Subjects scheduled to receive radiotherapy (RT) to a site of pain during the study period, or who have received RT to a site of pain within 2 weeks before study entry. 5. Subjects scheduled to undergo surgical treatment during the study period are likely to affect pain. 6. Subjects on or starting chemotherapy if there is a significant expectation of that therapy affecting pain. 7. Patients are included in other study group

Design outcomes

Primary

MeasureTime frame
1. To assess efficacy( in terms of changing NRS) of low dose intravenous ketamine in opioid refractory cancer pain in patients suffering from advanced cancer. 2. To assess safety (in terms of adverse effects )of low dose intravenous ketamine in opioid refractory cancer pain in patients suffering from advanced cancerTimepoint: 1. The first follow up will be done at 2nd week after discharge pain intensity and dose of opioid. 2. The second follow up will be done at 4th week after discharge regarding pain intensity and dose of opioid—

Secondary

MeasureTime frame
adverse events & sustainability of ketamine effect.Timepoint: at time of discharge at second week & fourth week of discharge.—

Countries

India

Contacts

Public ContactDR YOGENDRA SINGHAL

SAWAI MAN SINGH MEDICAL COLLEGE AND ATTACHED HOSPITALS JAIPUR

singhalyogi@yahoo.co.in9414850381

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026